Exagen Inc. will announce Q2 2025 financial results on July 29, 2025, with a conference call at 8:30 a.m. ET.
Quiver AI Summary
Exagen Inc. will announce its financial results for the second quarter of 2025 on July 29, 2025, before the market opens. CEO John Aballi and CFO Jeff Black will host a conference call at 8:30 a.m. ET to discuss the results, which can be accessed by phone or via a webcast link on their investor relations website. A replay of the call will be available until August 12, 2025. Exagen, based in Carlsbad, California, specializes in autoimmune diagnostics, aiming to aid in the diagnosis and management of chronic autoimmune conditions with its AVISE® testing portfolio. The company focuses on improving clinical outcomes and decision-making for conditions like lupus and rheumatoid arthritis.
Potential Positives
- Exagen Inc. will announce its financial results for Q2 2025, providing transparency and updates to investors and stakeholders on the company's performance.
- The scheduled conference call for reviewing financial results indicates an open line of communication between the company's leadership and the investment community, fostering investor relations.
- Exagen's commitment to transforming care for patients with autoimmune conditions underscores its position as a leader in the innovative diagnostics field, potentially attracting further interest from healthcare providers and investors.
- The company highlights its flagship product AVISE® CTD, which supports clinicians in diagnosing complex autoimmune conditions, enhancing its credibility and relevance in the medical community.
Potential Negatives
- None
FAQ
When will Exagen release its financial results for Q2 2025?
Exagen will release its financial results for the quarter ended June 30, 2025, on Tuesday, July 29, 2025.
Who will host the conference call for Exagen's financial results?
The conference call will be hosted by John Aballi, President and CEO, and Jeff Black, CFO of Exagen.
How can I access Exagen's conference call?
You can access the conference call by dialing 201-389-0918 (U.S.) or +1-877-407-0890 (international).
Will there be a replay available for Exagen's conference call?
Yes, a replay will be available until Tuesday, August 12, 2025, by dialing 201-612-7415 (U.S.) or +1-877-660-6853 (international).
What is Exagen's primary focus in the healthcare industry?
Exagen focuses on innovative autoimmune diagnostics, aiming to improve clinical outcomes for patients with autoimmune conditions.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$XGN Insider Trading Activity
$XGN insiders have traded $XGN stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $XGN stock by insiders over the last 6 months:
- CO-INVESTMENT FUND, L.P. NMSIC sold 350,000 shares for an estimated $1,155,000
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$XGN Hedge Fund Activity
We have seen 12 institutional investors add shares of $XGN stock to their portfolio, and 19 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- HUDSON BAY CAPITAL MANAGEMENT LP added 166,705 shares (+inf%) to their portfolio in Q1 2025, for an estimated $598,470
- STONEPINE CAPITAL MANAGEMENT, LLC removed 155,302 shares (-61.9%) from their portfolio in Q1 2025, for an estimated $557,534
- KENNEDY CAPITAL MANAGEMENT LLC added 110,680 shares (+60.0%) to their portfolio in Q1 2025, for an estimated $397,341
- MARSHALL WACE, LLP added 90,511 shares (+564.0%) to their portfolio in Q1 2025, for an estimated $324,934
- HUNTLEIGH ADVISORS, INC. removed 71,169 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $255,496
- WASATCH ADVISORS LP removed 42,975 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $154,280
- CREATIVE PLANNING removed 35,500 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $127,445
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$XGN Analyst Ratings
Wall Street analysts have issued reports on $XGN in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Cantor Fitzgerald issued a "Overweight" rating on 05/15/2025
- Canaccord Genuity issued a "Buy" rating on 05/13/2025
To track analyst ratings and price targets for $XGN, check out Quiver Quantitative's $XGN forecast page.
$XGN Price Targets
Multiple analysts have issued price targets for $XGN recently. We have seen 2 analysts offer price targets for $XGN in the last 6 months, with a median target of $7.5.
Here are some recent targets:
- Ross Osborn from Cantor Fitzgerald set a target price of $7.0 on 05/15/2025
- Kyle Mikson from Canaccord Genuity set a target price of $8.0 on 05/13/2025
Full Release
CARLSBAD, Calif., July 15, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended June 30, 2025, before the market opens on Tuesday, July 29, 2025. John Aballi, Exagen’s President and Chief Executive Officer, and Jeff Black, Chief Financial Officer, will host a conference call to review the company’s results at 8:30 a.m. ET (5:30 a.m. PT).
Interested parties may access the conference call by dialing 201-389-0918 (U.S.) or +1-877-407-0890 (international). Participants wishing to access the call via webcast should use the link posted on the Exagen investor relations website at investors.exagen.com .
A replay of the conference call will be available until Tuesday, August 12, 2025. Interested parties may access the replay by dialing 201-612-7415 (U.S.) or +1-877-660-6853 (international) using passcode 13753132. Additionally, a recording of the webcast will be available using the link on the Exagen investor relations website approximately one hour after the call concludes.
About Exagen Inc.
Exagen Inc. (Nasdaq: XGN) is a leading provider of autoimmune diagnostics, committed to transforming care for patients with chronic and debilitating autoimmune conditions. Based in San Diego County, California, Exagen’s mission is to provide clarity in autoimmune disease decision-making and improve clinical outcomes through its innovative testing portfolio. The company’s flagship product, AVISE® CTD, enables clinicians to more effectively diagnose complex autoimmune conditions such as lupus, rheumatoid arthritis, and Sjögren’s syndrome earlier and with greater accuracy. Exagen’s laboratory specializes in the testing of rheumatic diseases, delivering precise and timely results, supported by a full suite of AVISE-branded tests for disease diagnosis, prognosis, and monitoring. With a focus on research, innovation, education, and patient-centered care, Exagen is dedicated to addressing the ongoing challenges of autoimmune disease management.
For more information, visit Exagen.com or follow @ExagenInc on X .
Contact:
Ryan Douglas
Exagen Inc.
[email protected]
760.560.1525
